These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 9329054)

  • 1. Behavioral and neurochemical effects induced by subchronic l-deprenyl administration.
    Molinengo L; Ghi P
    Pharmacol Biochem Behav; 1997 Nov; 58(3):649-55. PubMed ID: 9329054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Behavioral and neurochemical effects of a chronic choline-deficient diet in the rat.
    Molinengo L; Orsetti M; Ghi P
    Behav Brain Res; 1997 Mar; 84(1-2):145-50. PubMed ID: 9079780
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rat striatal monoamine oxidase-B inhibition by l-deprenyl and rasagiline: its relationship to 2-phenylethylamine-induced stereotypy and Parkinson's disease.
    Youdim MB; Tipton KF
    Parkinsonism Relat Disord; 2002 Mar; 8(4):247-53. PubMed ID: 12039419
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Region-specific alterations in the concentrations of catecholamines and indoleamines in the brains of young and old F344 rats after L-deprenyl treatment.
    ThyagaRajan S; Stevens SY; Felten DL
    Brain Res Bull; 1999 Mar; 48(5):513-20. PubMed ID: 10372512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of long-term treatment with selective monoamine oxidase A and B inhibitors on dopamine release from rat striatum in vivo.
    Lamensdorf I; Youdim MB; Finberg JP
    J Neurochem; 1996 Oct; 67(4):1532-9. PubMed ID: 8858937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deficits in cholinergic neurotransmission markers induced by ethylcholine mustard aziridinium (AF64A) in the rat hippocampus: sensitivity to treatment with the monoamine oxidase-B inhibitor L-deprenyl.
    Ricci A; Mancini M; Strocchi P; Bongrani S; Bronzetti E
    Drugs Exp Clin Res; 1992; 18(5):163-71. PubMed ID: 1490432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiple, small dose administration of (-)deprenyl enhances catecholaminergic activity and diminishes serotoninergic activity in the brain and these effects are unrelated to MAO-B inhibition.
    Knoll J; Miklya I
    Arch Int Pharmacodyn Ther; 1994; 328(1):1-15. PubMed ID: 7893186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic L-deprenyl treatment alters brain monoamine levels and reduces impulsiveness in an animal model of Attention-Deficit/Hyperactivity Disorder.
    Boix F; Qiao SW; Kolpus T; Sagvolden T
    Behav Brain Res; 1998 Jul; 94(1):153-62. PubMed ID: 9708846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Behavioral and neurochemical modifications caused by chronic alpha-methylparatyrosine administration.
    Molinengo L; Ghi P; Oggero L; Orsetti M
    Pharmacol Biochem Behav; 1991 Jun; 39(2):437-42. PubMed ID: 1658818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. R-(-)-deprenyl (Selegiline, Movergan) facilitates the activity of the nigrostriatal dopaminergic neuron.
    Knoll J
    J Neural Transm Suppl; 1987; 25():45-66. PubMed ID: 2828537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A pharmacological analysis elucidating why, in contrast to (-)-deprenyl (selegiline), alpha-tocopherol was ineffective in the DATATOP study.
    Miklya I; Knoll B; Knoll J
    Life Sci; 2003 Apr; 72(23):2641-8. PubMed ID: 12672509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Different effects of monoamine oxidase inhibition on MPTP depletion of heart and brain catecholamines in mice.
    Fuller RW; Hemrick-Luecke SK; Kindt MV; Heikkila RE
    Life Sci; 1988; 42(3):263-71. PubMed ID: 3121972
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of gestational exposure to monoamine oxidase inhibitors in rats: preliminary behavioral and neurochemical studies.
    Whitaker-Azmitia PM; Zhang X; Clarke C
    Neuropsychopharmacology; 1994 Oct; 11(2):125-32. PubMed ID: 7840864
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of MAO inhibitors on the uptake and metabolism of dopamine in rat and human brain.
    Tekes K; Tóthfalusi L; Gaál J; Magyar K
    Pol J Pharmacol Pharm; 1988; 40(6):653-8. PubMed ID: 3152003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Behavioral and neurochemical effects induced by chronic L-DOPA administration.
    Molinengo L; Scordo I; Pastorello B; Orsetti M; Ghi P
    Pharmacol Biochem Behav; 1996 Aug; 54(4):779-85. PubMed ID: 8853203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of monoamine oxidase-B by (-)-deprenyl potentiates neuronal responses to dopamine agonists but does not inhibit dopamine catabolism in the rat striatum.
    Paterson IA; Juorio AV; Berry MD; Zhu MY
    J Pharmacol Exp Ther; 1991 Sep; 258(3):1019-26. PubMed ID: 1679846
    [TBL] [Abstract][Full Text] [Related]  

  • 17. L-3,4-dihydroxyphenylalanine-induced dopamine release in the striatum of intact and 6-hydroxydopamine-treated rats: differential effects of monoamine oxidase A and B inhibitors.
    Wachtel SR; Abercrombie ED
    J Neurochem; 1994 Jul; 63(1):108-17. PubMed ID: 8207420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline.
    Kupsch A; Sautter J; Götz ME; Breithaupt W; Schwarz J; Youdim MB; Riederer P; Gerlach M; Oertel WH
    J Neural Transm (Vienna); 2001; 108(8-9):985-1009. PubMed ID: 11716151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SL25.1131 [3(S),3a(S)-3-methoxymethyl-7-[4,4,4-trifluorobutoxy]-3,3a,4,5-tetrahydro-1,3-oxazolo[3,4-a]quinolin-1-one], a new, reversible, and mixed inhibitor of monoamine oxidase-A and monoamine oxidase-B: biochemical and behavioral profile.
    Aubin N; Barneoud P; Carter C; Caille D; Sontag N; Marc C; Lolivier J; Gardes A; Perron C; Le Kim A; Charieras T; Pandini M; Burnier P; Puech F; Jegham S; George P; Scatton B; Curet O
    J Pharmacol Exp Ther; 2004 Sep; 310(3):1171-82. PubMed ID: 15178694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monoamine oxidase activity and monoamine metabolism in brains of parkinsonian patients treated with l-deprenyl.
    Riederer P; Youdim MB
    J Neurochem; 1986 May; 46(5):1359-65. PubMed ID: 2420928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.